Baxter Intl Inc Stock Price, News & Analysis

Baxter International Inc. (NYSE:BAX) introduced several innovative surgical solutions at the AORN Global Surgical Conference & Expo 2023 held from April 1-4, 2023. Key products include a new conductive Patient Warming System that minimizes risks linked to forced air warming and is designed to maintain body temperature effectively. The Helux Pro Connected Surgical Light enhances visibility during procedures with deep cavity lighting and a 4K camera. Additionally, the Floseal + Recothrom hemostat, utilizing recombinant thrombin, offers a faster preparation time and eliminates reliance on human blood products. These advancements aim to enhance patient care and efficiency in surgical settings.

Baxter International Inc. (NYSE:BAX) will hold its 2023 Annual Meeting of Stockholders virtually on May 2, 2023, at 9 a.m. Central Time. Online access begins at 8:30 a.m.. Stockholders are encouraged to vote their shares beforehand through proxy materials as in-person attendance is not allowed. Questions can be submitted in advance from April 28 to May 1 or live during the meeting. Those wishing to join as guests can listen-only, without voting or asking questions. Baxter emphasizes its long-standing commitment to innovation in healthcare, serving millions worldwide.

Baxter International Inc. (NYSE:BAX) declared a quarterly cash dividend of $0.29 per share, payable on April 3, 2023, to shareholders of record as of February 24, 2023. This indicates an annual dividend rate of $1.16 per share. The company has a rich history of over 90 years in providing healthcare solutions across more than 100 countries. This dividend declaration reflects Baxter's commitment to returning value to its shareholders amidst a stable operational strategy.

Baxter International reported a Q4 2022 sales increase of 11% to $3.9 billion, with 18% growth for the full year at $15.1 billion. Fourth-quarter U.S. GAAP diluted EPS was $0.36, adjusted EPS $0.88. Full-year U.S. GAAP diluted loss per share was ($4.83), adjusted EPS at $3.50, down 3% year-over-year. The company faces ongoing macroeconomic challenges, leading to plans for a spinoff of its Renal Care and Acute Therapies businesses. Baxter’s cost reduction initiatives aim to save over $300 million in 2023, with a workforce reduction of less than 5%.

Baxter International Inc. (NYSE:BAX) will hold a conference call on February 9, 2023, at 7:30 a.m. Central Time to discuss its fourth-quarter 2022 financial results. Interested participants can pre-register through the provided link or access the call via Baxter’s website. The call will also be recorded for future reference. Baxter continues to be a leader in healthcare with a diverse portfolio including critical care, kidney care, and surgical products utilized globally. For more insights, visit www.baxter.com.

Baxter International Inc. (NYSE:BAX) has announced plans to spin off its Renal Care and Acute Therapies units into a publicly traded company within 12-18 months. This restructuring aims to simplify operations, enhance strategic focus, and improve long-term performance. Additionally, Baxter will explore strategic alternatives for its BioPharma Solutions business to optimize its capital structure. The proposed changes are designed to strengthen Baxter's market position and foster innovation, with sales for the renal unit in 2021 reaching $5 billion.

The ExactaMix Pro Automated Compounder from Baxter International (NYSE:BAX), set for release in early 2023, enhances security and user experience while offering superior data reporting capabilities. It will be showcased at the ASHP Midyear Clinical Meeting from Dec. 4-8, 2022. This advanced system is certified to the FDA-recognized UL 2900-2-1 cybersecurity standard and provides features designed for increased efficiency and ease of use, including touchscreen responsiveness and 15 months of data storage. ExactaMix Pro signals a significant advancement in compounding technology.

Baxter International Inc. (NYSE:BAX) will participate in the 5th Annual Evercore ISI HealthCONx Conference on December 1, 2022, at 1:00 p.m. Eastern Time. Chief Financial Officer Jay Saccaro will present at the event. A live webcast will be available on www.baxter.com and can be replayed until May 30, 2023. With a legacy of 90 years, Baxter continues to innovate in areas like diagnostic and critical care solutions across over 100 countries, helping millions of patients and caregivers globally.